Answers are grounded in this paper and cite their sources.
Viloxazine extended-release demonstrated statistically significant and clinically meaningful improvement in ADHD symptoms in adolescents and was generally well tolerated.
No takes yet. Share an insight, caveat, or question.
Nasser et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: